Literature DB >> 16734860

Toxic factors in human urine that injure urothelium.

Mahadevan Rajasekaran1, Paul Stein, C Lowell Parsons.   

Abstract

AIM: Loss of the lower urinary permeability barrier and passive potassium cycling into tissue are an initiating event in interstitial cystitis. We tested whether a low molecular weight cytotoxic fraction from normal urine causes sensitivity to intravesical potassium in rats and whether the sulfated anionic polysaccharide pentosan polysulfate can neutralize this fraction's cytotoxic activity.
METHODS: A low molecular weight (> 100 < 3500) toxic urinary fraction was prepared from normal human urine by dialysis and the lyophilized, salt free product (toxic factor) further investigated. Anaesthetized adult male Sprague-Dawley rats received intravesical sodium or potassium, and urodynamic parameters, including number of voids and non-voiding contractions, were recorded. Then protamine sulfate, rehydrated toxic factor, or toxic factor plus pentosan polysulfate was infused, followed by potassium, and urodynamic measurements repeated. The toxic factor was evaluated in a commercial cytotoxicity protocol using cultured rat urothelial cells.
RESULTS: Rat bladder non-voiding contractions increased markedly over baseline when potassium was infused after toxic factor (1.681 +/- 0.1131 non-voiding contractions/min; P = 0.0004) but not after toxic factor premixed with pentosan polysulfate. Toxic factor had a significant (P < 0.001) cytotoxic effect in cultured rat bladder epithelial cells; toxic factor plus pentosan polysulfate was significantly less cytotoxic than toxic factor alone (P < 0.007).
CONCLUSIONS: Normal urine contains a cationic cytotoxic factor that increases urothelial permeability by injuring the mucosa, allowing potassium to penetrate the urothelium and depolarize the underlying nerves and muscles. Pentosan polysulfate neutralizes the toxic factor, attenuates urothelial damage, and suppresses potassium-mediated bladder hyperactivity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16734860     DOI: 10.1111/j.1442-2042.2006.01301.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  11 in total

Review 1.  Idiopathic cystitis in domestic cats--beyond the lower urinary tract.

Authors:  C A T Buffington
Journal:  J Vet Intern Med       Date:  2011-05-12       Impact factor: 3.333

2.  Intravesical chondroitin sulfate inhibits recruitment of inflammatory cells in an acute acid damage "leaky bladder" model of cystitis.

Authors:  Christopher D Engles; Paul J Hauser; Shivon N Abdullah; Daniel J Culkin; Robert E Hurst
Journal:  Urology       Date:  2011-12-02       Impact factor: 2.649

3.  Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis.

Authors:  Daniele Porru; Fabio Leva; Alberto Parmigiani; Davide Barletta; Dimitrios Choussos; Barbara Gardella; Maria Diletta Daccò; Rossella Elena Nappi; Massimo Allegri; Carmine Tinelli; Carlo Maria Bianchi; Arsenio Spinillo; Bruno Rovereto
Journal:  Int Urogynecol J       Date:  2011-09-09       Impact factor: 2.894

Review 4.  Prevalence, Risk Factors, Pathophysiology, Potential Biomarkers and Management of Feline Idiopathic Cystitis: An Update Review.

Authors:  Chengxi He; Kai Fan; Zhihui Hao; Na Tang; Gebin Li; Shuaiyu Wang
Journal:  Front Vet Sci       Date:  2022-06-21

5.  Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate.

Authors:  Paul J Hauser; David A Buethe; John Califano; Troy M Sofinowski; Daniel J Culkin; Robert E Hurst
Journal:  J Urol       Date:  2009-09-17       Impact factor: 7.450

6.  Increased toxic urinary cations in males with interstitial cystitis: a possible cause of bladder symptoms.

Authors:  Sulabha Argade; Zoltan Berecz; Yongxuan Su; C Lowell Parsons
Journal:  World J Urol       Date:  2016-03-30       Impact factor: 4.226

7.  Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain.

Authors:  W F Goins; J R Goss; M B Chancellor; W C de Groat; J C Glorioso; N Yoshimura
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

8.  The role of TSG-6 and uroplakin III in bladder pain syndrome/ interstitial cystitis in rats and humans.

Authors:  Yi-Song Lv; Rui Gao; Qing-Ming Lin; Tao Jiang; Qin Chen; Song-Xi Tang; Hou-Ping Mao; Hui-Liang Zhou; Lin-Sheng Cao
Journal:  Iran J Basic Med Sci       Date:  2017-11       Impact factor: 2.699

Review 9.  Review of intravesical therapies for bladder pain syndrome/interstitial cystitis.

Authors:  Kristina Cvach; Anna Rosamilia
Journal:  Transl Androl Urol       Date:  2015-12

Review 10.  Concise Review: Tissue Engineering of Urinary Bladder; We Still Have a Long Way to Go?

Authors:  Jan Adamowicz; Marta Pokrywczynska; Shane Vontelin Van Breda; Tomasz Kloskowski; Tomasz Drewa
Journal:  Stem Cells Transl Med       Date:  2017-10-10       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.